On April 21, 2025 Acepodia (6976: TT) reported the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC) (Press release, Acepodia, APR 21, 2025, View Source [SID1234652001]). The data will be featured at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025, which will take place from April 25 to April 30, 2025 in Chicago, Illinois.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presentation, titled "Development of dual-payload anti-GPC3 antibody-drug conjugate by dual-payload antibody conjugation (AD2C) platform for hepatocellular carcinoma treatment," showcases the company’s next-generation ADC generated using Acepodia’s AD2C platform. This platform allows for the conjugation of two distinct payloads to a single antibody without the need of antibody engineering or enzymatic conjugation. AD2C, carrying payloads with different mechanisms of action, offer enhanced therapeutic potency by targeting diverse cell populations in heterogeneous tumors or overcoming resistance to single-payload therapy.
Presentation Details:
Session Title: Novel Drug Delivery Technologies
Session Category: Experimental and Molecular Therapeutics
Date and Time: April 28, 2025 | 9:00 AM – 12:00 PM CDT
Location: McCormick Place Convention Center, Chicago, IL
Poster Board Number: 4 | Poster Section: 23
Abstract Number: 1785
"Acepodia’s dual-payload ADC approach is designed to address key limitations of current single-payload therapies," said Dr. Sonny Hsiao, Chairman and CEO of Acepodia. "By combining targeted delivery with enhanced cytotoxicity, this platform holds promise for more effective treatment of liver cancer and other solid tumors." AD2C platform provides a novel, antibody-engineering-free approach to generate dual-payload ADCs, offering a potential solution to tumor heterogeneity and drug resistance in cancer treatment.
The company’s AD2C pipeline is part of its broader portfolio of conjugation technologies derived from the laboratory of Nobel Laureate Dr. Carolyn Bertozzi, enabling the site-specific delivery of therapeutic payloads using bioorthogonal click chemistry.